Gemcitabine plus S-1 versus Cetuximab as Third-line Therapy for Metastatic Colorectal Cancer
(0) Objective: To assess the efficacy and safety of gemcitabine plus S-1 (GS) vs cetuximab as a third-line chemotherapy for metastatic colorectal cancer (mCRC) patients unresponsive to oxaliplatin, irinotecan, and 5-FU.Methods: Patients with previous failure of oxaliplatin, 5-FU, and irinotecan were included.The patients received gemcitabine plus S-1 or cetuximab until disease progression or intolerable toxicity occurred.Results: A total of 38 patients were enrolled between October 2009 and October 2012, and each group was 19.The median OS of the GS group was 10 months, and the cetuximab group was 6.9 months (P =0.047).For the GS and cetuximab groups, the median PFS was 79 days and 78 days (P =0.344),respectively, and the disease control rate (DCR) was 42.11％ and 47.37％ (P =0.985).The objective response rate (ORR) was0％ and 10.52％, respectively (P=0.169).Adverse events (AEs) related to chemotherapy were mild to moderate.Only grade 3～ 4 neutropenia was 21.1％ in the GS group.In the cetuximab group, the rash incidence rate was 89.6％.Conclusion: Gemcitabine plus S-1 is a promising and safe regimen as a third-line chemotherapy for refractory but good performance status mCRC patients.
邓婷 韩如冰 黄鼎智 李鸿立 张乐 巴一
天津医科大学附属肿瘤医院消化肿瘤内科
国内会议
第八届中国肿瘤内科大会、第三届中国肿瘤医师大会暨中国抗癌协会肿瘤临床化疗专业委员会2014年学术年会
北京
英文
501-502
2014-07-02（万方平台首次上网日期，不代表论文的发表时间）